Four Top Psychedelic Stock Picks for 2021

Monday, 04. January 2021 14:00

ATLANTA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 2020 was a banner year for investors in psychedelic companies as investors in Mind Medicine (MindMed) Inc. (OTCQB: MMEDF), 20/20 Global, Inc. (OTC: TWGL), Compass Pathways (NASDAQ: CMPS), and Numinus Wellness Inc. (OTC: LKYSF) saw their money triple and even quadruple. Psychedelic stocks are in a fast moving sector characterized by companies many analysts would consider speculative and overpriced; however, it is our opinion many psychedelic companies will continue to defy the rules of investing and bulldoze their way to higher prices in 2021. New leaders may emerge, but the reason for this increased interest in psychedelics is improved mental health. We have said it before, and we will say it again, the real money in psychedelics will be made from FDA approved drugs for the treatment of depression and mental health. Depression is a common mental disorder affecting more than 264 million people worldwide. Mental health experts find a strong link between loneliness and depression and drug overdoses. According to national drug abuse data, drug overdoses have increased 42% since Covid-19 reared its ugly head. As a result, mental health disorders are on the rise in every country and could cost the global economy up to $16 trillion annually by 2030. The numbers are staggering, but outweighed by the loss of human lives. Mental health is something every one of us should be talking about.

In the early 1970s research into psychedelic medicine basically stopped overnight. Governments all over the globe classified psychedelics as illegal on the grounds they were drugs of abuse and had no medical use. But was that the real reason? Many of us are not convinced everyone in government has our best interest in mind on every decision. In the U. S. alone, the Mental Health and Substance Abuse Services industry includes over 17,000 facilities with combined annual revenue of approximately $50 billion. Tack on ancillary services and revenues jump to over $300 billion. The global antidepressants market is expected to grow from $14.3 billion in 2019 to about $28.6 billion in 2020 as mental health issues are expected to surge due to the effects of the Covid-19 pandemic. Even though huge advances in modern medicine have been made since 1970, with the exception of serotonin and norepinephrine reuptake inhibitors in the 1980s and 1990s, the mental health industry has not had major advancements in pharmacological therapies for mood disorders until the FDA approved esketamine in March 2019. Johnson & Johnson developed the ketamine derivative and sell it as a nasal spray called Spravato, used for the treatment of depression.

With this information on psychedelic medicine in mind, here are four psychedelic stocks that could show huge returns to investors in 2021:

MindMed (OTCQB: MMEDF) offers the broadest and most diversified pipeline of psychedelic drugs in clinical development and R&D. According to the investor deck on MindMed's website, the Company estimates there is a $100+ billion global total addressable market for psychedelics. MindMed recently announced it would establish a digital medicine division known as Albert to research, develop and build an integrated technical platform and comprehensive toolset aimed at delivering psychedelic inspired medicines and experiential therapies combined with digital therapeutics. Digital therapeutics are evidence-based therapeutic interventions for patients to prevent, manage, or treat a mental disorder or disease.

MindMed currently has multiple FDA-approved trials going on in multiple jurisdictions and geographies, along with a drug development pipeline based on psychedelic substances including Psilocybin, LSD, MDMA, DMT and an Ibogaine derivative, 18-MC. Bruce Linton, the Founder and Former Chairman and CEO of Canopy Growth Corporation, serves as a member of MindMed's Board of Directors. Kevin O'Leary of Shark Tank fame, aka Mr. Wonderful, invested in MindMed in its $24.2 million funding round before going public on Canada's NEO Exchange. Mr. O'Leary is quoted as saying, "This could save lives, cure depression, help alcoholism, get people off opioids—why wouldn’t I want to be invested?" https://mindmed.co

20/20 Global (OTC Pink: TWGL) is a newcomer to the psychedelic field and is a fully reporting issuer with the US Securities and Exchange Commission. Ehave, another psychedelic company that is in digital therapeutics and developing a ketamine delivery platform called KetaDASH, sold 100% of its Mycotopia Therapies subsidiary to 20/20 Global Inc. for $350,000 while simultaneously acquiring approximately 75.77% of 20/20 Global’s outstanding shares from 20/20 Global’s management. 20/20 Global and Mycotopia Therapies will focus on the psychedelic space, as a majority owned subsidiary of Ehave. Mycotopia Therapy specializes in evidence-based research by offering a study of an individual's psychotherapy using psychedelic medicines aided by data collection and algorithms developed with the help of psychedelic practitioners. Ehave transferred its 10% interest in PsychedeliTech Inc., which is the owner of the PsyTech conferences, to Mycotopia Therapies. As a subsidiary of 20/20 Global, Mycotopia Therapies will own 10% of PsyTech along with psychedelic tour and travel related businesses. 20/20 Global will be seeking other business opportunities in the psychedelic space including psychedelic retreats and medicinal mushrooms. Shares of 20/20 Global traded from $0.20 to over $2.00 on the news, but have settled around the current level of $0.80.

Ehave CEO Ben Kaplan was appointed as Chairman and CEO of 20/20 Global. Jamaican investment banker, Mark Croskery, will also serve on the Board of 20/20 to assist with sourcing deal flow from the Caribbean, South America, and Central America, where a plethora of psychedelic deals are on the radar. Ehave said in its press release announcing the transaction it may distribute 20/20 Global shares to its shareholders in the future. With 75.77% of 20/20 Global’s shares tied up with one shareholder, this stock could get some legs on any positive news. https://www.mycotopiatherapies.com

Compass Pathways (NASDAQ: CMPS) is based in the U.K. and has a patented, synthesized investigational psilocybin formulation named COMP360, which is under phase 2 investigation for targeting treatment-resistant depression. Compass Pathways' biggest draw is its patent. It owns the patent for “methods of treating drug-resistant depression with a psilocybin formulation.” Compass Pathways is testing a synthetic form of psilocybin as a therapy for treatment-resistant depression. Most of the other companies are testing the organic version of the psychedelic compound that occurs naturally in magic mushrooms.

Even though Compass Pathways is a development-stage company with only one drug, in our opinion, the stock will be a home run if COMP360 can treat depression. If Compass Pathways gets approval for COMP360, it should be able to protect and commercialize the drug, since the Company should be able to receive up to 7.5 years of intellectual property protection in the U.S. and up to 11 years in the E.U. for COMP360. The Company was funded by investors like PayPal billionaire Peter Thiel and Christian Angermayer, the founder of Apeiron Investment Group. Compass Pathways lost $41.5 million in the first nine months of the year, versus a loss of $12 million in the same period in 2019. Compass had $196.5 million in cash at the end of the third quarter, which is enough to keep the Company afloat until 2023. If the sight of red ink makes your stomach queasy, take a look at Compass Pathways' website and its world class Board of Directors and Scientific Advisory Board might quell your fears. https://compasspathways.com

Numinus Wellness Inc. (OTC: LKYSF) is a Canadian that has been granted a license by Health Canada to cultivate, extract, and sell “naturally sourced, sustainable psilocybin”, otherwise known as hallucinogenic magic mushrooms. According to the Company, it’s the only publicly traded company in Canada that is allowed to do so. Numinus Wellness is also the owner of a dealer’s license under which it’s allowed to “import, export, possess, test and distribute MDMA, psilocybin, psilocin, DMT, and mescaline.” Numinus aims to make psychedelic-assisted psychotherapy accessible through a network of health centers that provide safe, controlled, and therapeutic environments in which patients can heal and become well. Numinus offers three pathways for psychedelic-assisted psychotherapy. First, a recent acquisition of Mindspace clinics allows Numinus to offer ketamine-assisted psychotherapy, which can be prescribed to address treatment-resistant depression. Second, Numinus plans to support patients in obtaining Special Access to psychedelic-assisted psychotherapies, pending approval of regulatory change, which will be offered through its clinics in Vancouver and Montreal. Third, Numinus is undertaking two compassionate access clinical trials for psilocybin & MDMA, which will be conducted in its Vancouver clinic.

Numinus Wellness has been trading high six-figure and low seven-figure dollar volume on a daily basis, so we want to mention it here. While Numinus Wellness appears to have a great business plan and some credible advisors, it does not file audited financials on the U. S. Securities and Exchange Commission's EDGAR System. Numinus Wellness has also not upgraded its OTC Markets profile from its predecessor company, Lucky Strike Resources. https://numinus.ca

DISCLAIMER: OTC Stock Review (OTCSR), which owns and operates OTCStockReview.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. OTCSR is NOT affiliated in any manner with any company mentioned herein. OTCSR and its affiliated companies is a news dissemination solutions provider and are not a registered broker/dealer/analyst/adviser. OTCSR holds no investment licenses and may not sell, offer to sell or offer to buy any security. OTCSR's market updates, news alerts and corporate profiles are not a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. OTCSR is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed OTCSR was compensated one thousand five hundred dollars for news coverage of current press releases issued by 20/20 Global by a non-affiliated third party. OTCSR DOES NOT HOLD SHARES OF ANY COMPANIES NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and OTCSR undertakes no obligation to update such statements.

Contact Information:

David Kugelman

(404) 856-9157 Office

(866) 692-6847 Toll Free - U.S. & Canada

dk@otcstockreview.com

https://www.linkedin.com/in/davidkugelman 


Primary Logo

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.